Glabridin Alleviates Oxidative Stress-Induced Osteoporosis by Targeting the Akt/NF-ĸB and Akt/GSK-3β Pathways

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Diabetes-related osteoporosis is a growing concern linked to oxidative stress from reactive oxygen species (ROS).
• Current treatments for this condition often have adverse side effects, highlighting the need for safer alternatives.
• Glabridin, known for its hypoglycemic and antioxidant properties, is a potential candidate for managing diabetes-related osteoporosis.

Purpose of the Study:

• To investigate the preventive effects of glabridin against oxidative stress-induced bone loss in a diabetic rat model.
• To elucidate the underlying mechanisms by which glabridin exerts its protective effects on bone health.
• To assess the safety and efficacy of glabridin in vitro on preosteoblast cells.

Main Methods:

• A diabetic rat model was induced using streptozotocin, followed by daily oral administration of glabridin or glyburide for 8 weeks.
• Bone parameters including tibia length, thickness, epiphyseal plate length, and collagen deposition were measured.
• In vitro studies involved treating MC3T3-E1 preosteoblasts with glabridin to assess cytotoxicity, proliferation, ROS production, antioxidant enzyme activity, and apoptosis.

Main Results:

• Glabridin treatment significantly reversed diabetes-induced reductions in bone length, thickness, epiphyseal plate length, and collagen deposition.
• In vitro, glabridin (up to 7.5 µM) showed no cytotoxicity and prevented oxidative stress-induced inhibition of preosteoblast proliferation.
• Glabridin diminished ROS production, restored antioxidant enzyme activity, and reduced apoptosis by stimulating Akt, GSK-3β, and P65 NF-ĸB phosphorylation.

Conclusions:

• Glabridin demonstrates significant preventive effects against oxidative stress-induced bone loss in diabetes.
• The protective mechanisms involve modulating the Akt/NF-ĸB and Akt/GSK-3β pathways, reducing oxidative stress and osteoblast apoptosis.
• Glabridin presents a promising therapeutic agent for diabetes-related osteoporosis due to its efficacy and lack of cytotoxicity.